Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

详细信息    查看全文

• 作者：Satoshi Watanabe ; Takashi Sone ; Tomoharu Matsui ; Kenta Yamamura ; Mayuko Tani ; Akihito Okazaki ; Koji Kurokawa ; Yuichi Tambo ; Hazuki Takato ; Noriyuki Ohkura ; Yuko Waseda ; Nobuyuki Katayama ; Kazuo Kasahara
• 关键词：Small cell lung cancer ; Transformation ; EGFR tyrosine kinase inhibitors ; Adenocarcinoma ; Resistance ; NSE ; ProGRP
• 刊名：Lung Cancer
• 出版年：November, 2013
• 年：2013
• 卷：82
• 期：2
• 页码：370-372
• 全文大小：1270 K

文摘

We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to standard SCLC treatment. Tumor markers, including ProGRP and NSE, were elevated. Transformation to SCLC is a mechanism for acquired resistance to EGFR-TKI therapy. Secondary biopsy is important for evaluation of genetic and histological changes and selection of appropriate treatment. Furthermore, ProGRP and NSE may be useful for early detection of SCLC transformation in cases resistant to EGFR-TKI therapy.